Development of a Novel Tropomyosin Receptor Kinase Inhibitor Based on Structure–Activity Relationships: Identification of a Promising Clinical Candidate
Synlett · 01.10.2025 · 36 (16) · 2565-2572
DOI: 10.1055/a-2551-5752 ↗Kurz gefasst
Fachartikel in der Zeitschrift Synlett, erschienen am 01.10.2025. Verfasst von Toshiya Ito und 7 weiteren Autor:innen. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Tropomyosin receptor kinase (TRK) inhibitors have emerged as promising therapeutic agents for various cancers. In this study, we report the discovery and characterization of CH7070868, a novel and potent TRK-selective inhibitor. Through structure–activity relationship studies, we optimized the lead compound (CH7057288) to achieve superior TRK inhibition while reducing the risk of drug–drug interactions (CYP3A4 induction). CH7070868 demonstrated high selectivity for TRK over other kinases (KDR and LCK) and exhibited potent inhibitory activity in both biochemical and cellular assays. Our findings suggest that CH7070868 represents a promising candidate for further development as a next-generation TRK inhibitor with an enhanced efficacy.
Zitieren
APA
Ito, T., Kinoshita, K., Tomizawa, M., Shinohara, S., Nishii, H., Tanaka, H., Kuramoto, S., & Oikawa, N. (2025). Development of a Novel Tropomyosin Receptor Kinase Inhibitor Based on Structure–Activity Relationships: Identification of a Promising Clinical Candidate. Synlett, 36(16), 2565-2572. https://doi.org/10.1055/a-2551-5752
Vancouver
Ito T, Kinoshita K, Tomizawa M, Shinohara S, Nishii H, Tanaka H, et al. Development of a Novel Tropomyosin Receptor Kinase Inhibitor Based on Structure–Activity Relationships: Identification of a Promising Clinical Candidate. Synlett. 2025;36(16):2565-2572. doi:10.1055/a-2551-5752
BibTeX
@article{Ito2025,
author = {Ito, Toshiya and Kinoshita, Kazutomo and Tomizawa, Masaki and Shinohara, Shojiro and Nishii, Hiroki and Tanaka, Hiroshi and Kuramoto, Shino and Oikawa, Nobuhiro},
title = {Development of a Novel Tropomyosin Receptor Kinase Inhibitor Based on Structure–Activity Relationships: Identification of a Promising Clinical Candidate},
journal = {Synlett},
year = {2025},
volume = {36},
number = {16},
pages = {2565--2572},
doi = {10.1055/a-2551-5752}
}
EUVIMED